Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
  • Investors
  • Careers

Optimizing RAS Inhibition with Dual Blockade of Oncogenic and Wild-Type RAS

June 14, 2023

M. Holderfield, S. Cai, J. Dinglasan, N. Montazer, L. Lai, B. Lee, K. Yang, J.A.M. Smith, M. Singh, D. Wildes

 

European Association for Cancer Research (EACR) Annual Congress 2023; June 12-15, 2023.  Presentation OP-26.

 

Download presentation
Return to Media Home

Latest Scientific Presentations

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Optimizing RAS Inhibition with Dual Blockade of Oncogenic and Wild-Type RAS
Combinations of Tri-complex KRAS(ON) Inhibitors with RAS Companion Inhibitors and Immunotherapies Improve Anti-tumor Activity and Abrogate Adaptive Resistance in Preclinical Tumor Models In Vivo
Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us